CA2310926C - A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease - Google Patents

A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease Download PDF

Info

Publication number
CA2310926C
CA2310926C CA002310926A CA2310926A CA2310926C CA 2310926 C CA2310926 C CA 2310926C CA 002310926 A CA002310926 A CA 002310926A CA 2310926 A CA2310926 A CA 2310926A CA 2310926 C CA2310926 C CA 2310926C
Authority
CA
Canada
Prior art keywords
day
galantamine
treatment
weeks
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002310926A
Other languages
English (en)
French (fr)
Other versions
CA2310926A1 (en
Inventor
Wim Louis Julien Parys
Michael Pontecorvo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA2310926A1 publication Critical patent/CA2310926A1/en
Application granted granted Critical
Publication of CA2310926C publication Critical patent/CA2310926C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002310926A 2000-04-03 2000-06-27 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease Expired - Lifetime CA2310926C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
US60/194,259 2000-04-03

Publications (2)

Publication Number Publication Date
CA2310926A1 CA2310926A1 (en) 2000-10-04
CA2310926C true CA2310926C (en) 2002-10-15

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002310926A Expired - Lifetime CA2310926C (en) 2000-04-03 2000-06-27 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Country Status (20)

Country Link
EP (1) EP1272192A2 (hu)
JP (1) JP2003528913A (hu)
KR (1) KR20020086911A (hu)
CN (1) CN1430514A (hu)
AU (2) AU6584401A (hu)
BG (1) BG107093A (hu)
BR (1) BR0109770A (hu)
CA (1) CA2310926C (hu)
CZ (1) CZ20023543A3 (hu)
EE (1) EE200200554A (hu)
HR (1) HRP20020778A2 (hu)
HU (1) HUP0300566A3 (hu)
IL (1) IL152061A0 (hu)
MX (1) MXPA02009777A (hu)
NO (1) NO20024746L (hu)
PL (1) PL361272A1 (hu)
RU (1) RU2002129298A (hu)
SK (1) SK15422002A3 (hu)
WO (1) WO2001074339A2 (hu)
ZA (1) ZA200207935B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
EP1651234B1 (en) 2003-07-25 2007-09-26 F. Hoffmann-La Roche Ag Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
AU2009229372C1 (en) 2008-03-27 2017-02-02 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
BG66818B1 (bg) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
WO2016187339A1 (en) * 2015-05-18 2016-11-24 Synaptec Development Llc GALANTAMINE CLEARANCE OF AMYLOIDß
CN117957003A (zh) * 2021-09-09 2024-04-30 上海日馨医药科技股份有限公司 治疗神经退行性疾病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
ES2211215T3 (es) * 1998-12-24 2004-07-01 Janssen Pharmaceutica N.V. Composicion de galantamina de liberacion controlada.
CA2310990A1 (en) * 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects

Also Published As

Publication number Publication date
EE200200554A (et) 2004-04-15
CA2310926A1 (en) 2000-10-04
PL361272A1 (en) 2004-10-04
AU2001265844B2 (en) 2005-04-14
BR0109770A (pt) 2003-02-04
SK15422002A3 (sk) 2003-04-01
HUP0300566A3 (en) 2004-10-28
AU6584401A (en) 2001-10-15
ZA200207935B (en) 2004-01-30
MXPA02009777A (es) 2003-03-27
CZ20023543A3 (cs) 2003-03-12
BG107093A (bg) 2003-06-30
IL152061A0 (en) 2003-05-29
HUP0300566A2 (hu) 2003-06-28
CN1430514A (zh) 2003-07-16
EP1272192A2 (en) 2003-01-08
WO2001074339A3 (en) 2002-09-12
KR20020086911A (ko) 2002-11-20
WO2001074339A2 (en) 2001-10-11
NO20024746L (no) 2002-11-28
RU2002129298A (ru) 2004-03-27
JP2003528913A (ja) 2003-09-30
HRP20020778A2 (en) 2004-04-30
NO20024746D0 (no) 2002-10-02

Similar Documents

Publication Publication Date Title
AU621035B2 (en) The administration of monoamine acridines in cholinergic neuronal deficit states
Granacher et al. Physostigmine: Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs
JP4097285B2 (ja) 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
CA2310950C (en) An efficacious dosage regiment of galantamine that reduces side effects
US7943632B2 (en) High potency dopaminergic treatment of neurological impairment associated with brain injury
CA2310926C (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
KR20220012281A (ko) 브루톤 티로신 키나제 저해제를 이용하여 만성 자발성 두드러기를 치료하는 방법
AU2001265844A1 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
Dalton et al. Cimetidine and carbamazepine: a complex drug interaction
US20060172993A1 (en) Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease
Stanaland Treatment of patients with chronic idiopathic urticaria
WO2015153263A1 (en) Compositions and methods to treat addiction
US11389420B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
US20050203105A1 (en) Composition and method for controlling alcohol-induced facial flushing in susceptible humans
JP2005306882A (ja) 感情的不安定の治療のための医薬の製造に有用な組成物
Panas et al. Belladonna alkaloids and phenobarbital use in the treatment of irritable bowel syndrome: a review
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
RU2818678C2 (ru) Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона
US11752141B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
Flowers et al. Antihistamines.
JP4372723B2 (ja) 慢性疼痛の治療のための医薬の製造に有用な組成物
de Haen Annual Review of New Drugs

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200629